Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -6.18% is in line with its 1-year average of -6.28%, around the middle of its 1-year range (-12.09%–-1.69%).
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -6.07%.
NET PROFIT MARGIN
-6.18%
NET PROFIT MARGIN AVG TTM
N/A
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-2276.92%
vs the sector median at left
Starling Oncology, Inc.
Market Cap
$658.68M
Net Profit Margin
-6.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$660.17M
Net Profit Margin
329.09%
TTM Avg
-11813.45%
3Y Avg
-10636.53%
5Y Avg
-14431.57%
Market Cap
$656.86M
Net Profit Margin
-194.74%
TTM Avg
-217471.40%
3Y Avg
-109716.20%
5Y Avg
-73279.44%
Market Cap
$666.85M
Net Profit Margin
1.76%
TTM Avg
11.88%
3Y Avg
8.37%
5Y Avg
1.42%
Market Cap
$672.56M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-265.57%
5Y Avg
-265.38%
Market Cap
$676.73M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$633.06M
Net Profit Margin
-4613.11%
TTM Avg
-5454.52%
3Y Avg
-2727.26%
5Y Avg
-1829.08%
Market Cap
$632.49M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $658.68M | -6.18% | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $660.17M | 329.09% | -11813.45% | -10636.53% | -14431.57% |
| Annexon, Inc. (ANNX)vs › | $660.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.86M | -194.74% | -217471.40% | -109716.20% | -73279.44% |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 1.76% | 11.88% | 8.37% | 1.42% |
| Solid Biosciences Inc. (SLDB)vs › | $672.56M | 0.00% | 0.00% | -265.57% | -265.38% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $676.73M | 0.00% | 0.00% | 0.00% | 0.00% |
| Prime Medicine, Inc. (PRME)vs › | $633.06M | -4613.11% | -5454.52% | -2727.26% | -1829.08% |
| Aura Biosciences, Inc. (AURA)vs › | $632.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Verastem, Inc. (VSTM)vs › | $685.41M | -231.59% | -991.98% | -1206.82% | -1395.31% |
Operating Margin
-4.4%
Net Profit Margin
-6.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -6.07% |
| 2026-03-31 | -1.69% |
| 2025-12-31 | -5.29% |
| 2025-09-30 | -12.09% |